Linagliptin Inpatient Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.
Also called NCT02004366
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 295 participants
- Registry
-
NCT02004366
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02004366. Randomized; no masking; primary purpose treatment. Start 2014-01 (actual); primary completion 2017-02 (actual). Results posted on 2018-10-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Linagliptin Inpatient Trial
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Basal Bolus
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Linagliptin + 50% Glargine dose on discharge
- Intervention (Drug)
- Linagliptin + 80% Glargine
- Lead sponsor
- Emory University
- Collaborator
- Boston Medical Center
- Collaborator
- Rush University
- Collaborator
- University of Denver
Record details
- Record id
cardio:ct-nct02004366- Content hash
7901df4e47b6e2e490e9f7358a5175f7ff3c82ee664c129a561d387aa64a2c4a